Agenus Inc. (NASDAQ:AGEN) reported first-quarter 2016 loss of 37 cents per share, wider than the Zacks Consensus Estimate of a loss of 23 cents and the year-ago loss of 28 cents.
Revenues surged 50.7% year over year to almost $6 million. Revenues, however, failed to beat the Zacks Consensus Estimate of $7 million.
Quarter in Detail
Agenus’ first-quarter research and development (R&D) expenses surged 171.6% to $25 million. Likewise, general and administrative expenses shot up 68.3% to $9.2 million.
Pipeline Update
Agenus is progressing with the development of its Prophage vaccine, which is scheduled to enter phase III study for newly-diagnosed glioblastoma in 2016. The company also plans to evaluate Prophage in combination with other approved and/or experimental immunotherapeutic agents.
Agenus received a major boost when the FDA cleared its Investigational New Drug (IND) application for AGEN1884 and INCAGN01876. A phase I study on AGEN1884 has been initiated to treat solid tumors.
Meanwhile, Agenus’ partner GlaxoSmithKline’s (NYSE:GSK) intends to submit regulatory application for its shingles vaccine candidate, Shingrix, which contains Agenus’ QS-21 Stimulon adjuvant, in the second half of 2016.
In addition, the company expects to initiate a phase I study on experimental vaccine, AutoSynVax, in 2016.
Our Take
Agenus first-quarter results were disappointing with the company reporting a wider-than-expected loss and missing bottom-line estimates. However, we are encouraged by the company’s efforts to develop its pipeline and expect investor focus on further updates from the company regarding Prophage and other programs.
Agenus currently carries a Zacks Rank #4 (Sell). A couple of better-ranked stocks in the health care sector are Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) and Emergent BioSolutions, Inc. (NYSE:EBS) , both sporting a Zacks Rank #1 (Strong Buy).
GLAXOSMITHKLINE (GSK): Free Stock Analysis Report
AEGERION PHARMA (AEGR): Free Stock Analysis Report
AGENUS INC (AGEN): Free Stock Analysis Report
EMERGENT BIOSOL (EBS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Agenus' (AGEN) Q1 Loss Wider Than Expected, Revenue Miss
Published 04/28/2016, 11:41 PM
Updated 07/09/2023, 06:31 AM
Agenus' (AGEN) Q1 Loss Wider Than Expected, Revenue Miss
Latest comments
Loading next article…
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.